Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lisata Therapeutics, Inc. on June 26, 2025. The filing serves as a Regulation FD disclosure regarding the release of preliminary clinical trial data.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates rather than financial performance.
Material Changes and Clinical Updates
- Event: Announcement of preliminary Cohort B data from the Phase 2 ASCEND trial.
- Therapeutic Area: Metastatic pancreatic ductal adenocarcinoma.
- Investigational Product: Certepetide administered with standard-of-care chemotherapy.
- Documentation: The press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) are attached to this filing.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial outlook, or specific risk factors beyond the standard disclaimer that the clinical data is preliminary. The information provided in Item 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific efficacy and safety statistics from the ASCEND trial Cohort B.
- Examine Exhibit 99.2 (Corporate Presentation) for detailed data visualizations and trial design context.
- Verify the status of the Phase 2 ASCEND trial and any planned next steps for certepetide development.
- Check subsequent filings for any financial impact resulting from the clinical data release.